Biostar Pharmaceutic (BSPM) 2.18 $BSPM
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended June 30, 2016
PR Newswire - Mon Aug 22, 3:00PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the second quarter ended June 30, 2016.
BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2016
PR Newswire - Mon May 23, 3:00PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the first quarter ended March 31, 2016.
BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals, Inc. Announces Its Annual Results for The Year Ended December 31, 2015
PR Newswire - Thu Apr 14, 3:00PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the year ended December 31, 2015.
BSPM: 2.18 (+0.05)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 27.28 (-0.34), BSPM: 2.18 (+0.05), ADRO: 14.49 (+0.27), ARWR: 7.15 (+0.09), ARQL: 1.40 (unch), AMGN: 169.77 (-0.36), CASI: 1.19 (-0.03), BMY: 56.35 (-0.41), CLBS: 4.92 (+0.09), AAAP: 34.63 (+0.22), CANF: 2.36 (-0.11), ABUS: 3.76 (-0.03), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), ABBV: 64.12 (+0.09), XLRN: 30.84 (+0.59), ARRY: 3.50 (-0.02)
BUYINS.NET: BSPM SqueezeTrigger Price is $2.06. There is $17,430 That Short Sellers Still Need To Cover.
M2 - Fri Feb 05, 9:15AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Biostar Pharmaceuticals Inc (NASDAQ:BSPM) in real time and just received an alert that BSPM is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 8300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $2.06. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals to Effect Reverse Stock Split
PR Newswire - Fri Feb 05, 8:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that its Board of Directors unanimously approved a reverse split of its common stock at a ratio of 1-for-7, with anticipated trading on the post-split basis on NASDAQ commencing at the open of the stock market on February 5, 2016.
BSPM: 2.18 (+0.05)
World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 10.91 (-5.03), ABUS: 3.76 (-0.03), BSPM: 2.18 (+0.05), CMRX: 4.62 (unch), CVM: 0.43 (-0.05), ARWR: 7.15 (+0.09), ASMB: 6.13 (-0.12)
Biostar Pharmaceuticals Inc. Postpones its 2015 Annual Meeting of Shareholders
PR Newswire - Fri Dec 04, 3:00PM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar", "we" or the "Company" , a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced that the Company has decided to postpone the Annual Meeting of Shareholders (the "Annual Meeting" for lack of quorum to conduct business at the Annual Meeting. The Annual Meeting was originally scheduled to be held December 4, 2015, at the Company's offices in Xianyang City, Shaanxi Province, PRC.
BSPM: 2.18 (+0.05)
BiostarPharmaceuticals,Inc. Announces Its Quarterly Results for Three Months Ended September 30, 2015
PR Newswire - Mon Nov 23, 3:00PM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the third quarter ended September 30, 2015.
BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals,Inc. Announces Its Quarterly and Half Year Results for 2015
PR Newswire - Wed Aug 19, 3:30PM CDT
Financial Highlights for the Three and Six Months ended June 30, 2015
BSPM: 2.18 (+0.05)
Hepatitis B - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hepatitis B
M2 - Mon Aug 17, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvqbsr/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information Key Topics Covered: - Introduction - Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Abivax S.A. - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - AltraVax Inc. - Amarna Therapeutics B.V. - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - Big DNA Ltd. - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cytos Biotechnology AG - Dynavax Technologies Corporation For more information visit http://www.researchandmarkets.com/research/vv...epatitis_b
DVAX: 10.91 (-5.03), BSPM: 2.18 (+0.05), CMRX: 4.62 (unch), ARWR: 7.15 (+0.09), ASMB: 6.13 (-0.12)
Factors Moving Markets: Complementary Research on Biostar, China Gerui, AirMedia, Panera, Amedica
PR Newswire - Tue Apr 21, 8:42AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AMCN: 3.02 (-0.05), BSPM: 2.18 (+0.05), PNRA: 217.26 (+1.67), CHOP: 0.65 (unch), AMDA: 0.86 (-0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
IMDZ: 7.07 (-0.04), BSPM: 2.18 (+0.05), TZOO: 12.81 (+0.26), FOMX: 8.73 (+0.06), SLTC: 3.83 (-0.09), BIOD: 0.42 (unch), DSKX: 0.67 (-0.18), CLSN: 1.20 (-0.02), DOVR: 8.43 (+0.03), MRCC: 15.91 (-0.03), VGGL: 0.42 (unch), TGLS: 12.60 (-0.01), INPH: 0.04 (unch), CHNR: 1.77 (+0.02)
Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results
PR Newswire - Wed Apr 15, 3:30PM CDT
Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar", "we" or the "Company" , a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced its results of operations for the full year and the quarter ended December 31, 2014.
BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals, Inc. Announces Signing of Joint Research and Development Agreement with Northwest University for Further Development of Danshensu Yibingzhi (IDHP), a Class One Drug for Treatment of Cardiovascular Diseases
PR Newswire - Thu Jan 08, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on December 29, 2014, the Company signed a joint research and development agreement with Northwest University, one of China's leading comprehensive universities located in Xi'an city, Shaanxi Province, for further development of Danshensu Yibingzhi (IDHP), a Class One drug for treatment of cardiovascular diseases to further research and development efforts in connection with Danshensu Yibingzhi (IDHP).
BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended June 30, 2016
PR Newswire - Mon Aug 22, 3:00PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the second quarter ended June 30, 2016. BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2016
PR Newswire - Mon May 23, 3:00PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the first quarter ended March 31, 2016. BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals, Inc. Announces Its Annual Results for The Year Ended December 31, 2015
PR Newswire - Thu Apr 14, 3:00PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the year ended December 31, 2015. BSPM: 2.18 (+0.05)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 27.28 (-0.34), BSPM: 2.18 (+0.05), ADRO: 14.49 (+0.27), ARWR: 7.15 (+0.09), ARQL: 1.40 (unch), AMGN: 169.77 (-0.36), CASI: 1.19 (-0.03), BMY: 56.35 (-0.41), CLBS: 4.92 (+0.09), AAAP: 34.63 (+0.22), CANF: 2.36 (-0.11), ABUS: 3.76 (-0.03), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), ABBV: 64.12 (+0.09), XLRN: 30.84 (+0.59), ARRY: 3.50 (-0.02)
BUYINS.NET: BSPM SqueezeTrigger Price is $2.06. There is $17,430 That Short Sellers Still Need To Cover.
M2 - Fri Feb 05, 9:15AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Biostar Pharmaceuticals Inc (NASDAQ:BSPM) in real time and just received an alert that BSPM is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 8300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $2.06. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals to Effect Reverse Stock Split
PR Newswire - Fri Feb 05, 8:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that its Board of Directors unanimously approved a reverse split of its common stock at a ratio of 1-for-7, with anticipated trading on the post-split basis on NASDAQ commencing at the open of the stock market on February 5, 2016. BSPM: 2.18 (+0.05)
World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 10.91 (-5.03), ABUS: 3.76 (-0.03), BSPM: 2.18 (+0.05), CMRX: 4.62 (unch), CVM: 0.43 (-0.05), ARWR: 7.15 (+0.09), ASMB: 6.13 (-0.12)
Biostar Pharmaceuticals Inc. Postpones its 2015 Annual Meeting of Shareholders
PR Newswire - Fri Dec 04, 3:00PM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar", "we" or the "Company"
, a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced that the Company has decided to postpone the Annual Meeting of Shareholders (the "Annual Meeting" for lack of quorum to conduct business at the Annual Meeting. The Annual Meeting was originally scheduled to be held December 4, 2015, at the Company's offices in Xianyang City, Shaanxi Province, PRC. BSPM: 2.18 (+0.05)
BiostarPharmaceuticals,Inc. Announces Its Quarterly Results for Three Months Ended September 30, 2015
PR Newswire - Mon Nov 23, 3:00PM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the third quarter ended September 30, 2015. BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals,Inc. Announces Its Quarterly and Half Year Results for 2015
PR Newswire - Wed Aug 19, 3:30PM CDT
Financial Highlights for the Three and Six Months ended June 30, 2015
BSPM: 2.18 (+0.05)
Hepatitis B - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hepatitis B
M2 - Mon Aug 17, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvqbsr/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information Key Topics Covered: - Introduction - Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Abivax S.A. - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - AltraVax Inc. - Amarna Therapeutics B.V. - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - Big DNA Ltd. - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cytos Biotechnology AG - Dynavax Technologies Corporation For more information visit http://www.researchandmarkets.com/research/vv...epatitis_b
DVAX: 10.91 (-5.03), BSPM: 2.18 (+0.05), CMRX: 4.62 (unch), ARWR: 7.15 (+0.09), ASMB: 6.13 (-0.12)
Factors Moving Markets: Complementary Research on Biostar, China Gerui, AirMedia, Panera, Amedica
PR Newswire - Tue Apr 21, 8:42AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AMCN: 3.02 (-0.05), BSPM: 2.18 (+0.05), PNRA: 217.26 (+1.67), CHOP: 0.65 (unch), AMDA: 0.86 (-0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
IMDZ: 7.07 (-0.04), BSPM: 2.18 (+0.05), TZOO: 12.81 (+0.26), FOMX: 8.73 (+0.06), SLTC: 3.83 (-0.09), BIOD: 0.42 (unch), DSKX: 0.67 (-0.18), CLSN: 1.20 (-0.02), DOVR: 8.43 (+0.03), MRCC: 15.91 (-0.03), VGGL: 0.42 (unch), TGLS: 12.60 (-0.01), INPH: 0.04 (unch), CHNR: 1.77 (+0.02)
Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results
PR Newswire - Wed Apr 15, 3:30PM CDT
Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar", "we" or the "Company"
, a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced its results of operations for the full year and the quarter ended December 31, 2014. BSPM: 2.18 (+0.05)
Biostar Pharmaceuticals, Inc. Announces Signing of Joint Research and Development Agreement with Northwest University for Further Development of Danshensu Yibingzhi (IDHP), a Class One Drug for Treatment of Cardiovascular Diseases
PR Newswire - Thu Jan 08, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on December 29, 2014, the Company signed a joint research and development agreement with Northwest University, one of China's leading comprehensive universities located in Xi'an city, Shaanxi Province, for further development of Danshensu Yibingzhi (IDHP), a Class One drug for treatment of cardiovascular diseases to further research and development efforts in connection with Danshensu Yibingzhi (IDHP). BSPM: 2.18 (+0.05)
